LOS ANGELES -- (Business Wire)

Glancy Prongay & Murray LLP (“GPM”) announces that it is investigating potential claims on behalf of investors of Amicus Therapeutics, Inc. (“Amicus” or the “Company”) (NASDAQ: FOLD) concerning the Company’s and its officers’ possible violations of federal securities laws in connection with the Company’s recently announced delay in submitting a New Drug Application (“NDA”) to the Food and Drug Administration (“FDA”).

On October 2, 2015, the Company disclosed that the FDA had “requested further integration of existing clinical data across studies” in connection with Amicus’s migalastat monotherapy treatment for Fabry disease, and that, “Amicus does not anticipate being in a position to submit the NDA for migalastat monotherapy in the United States by the end of this year.” On this news, the Company’s stock fell $7.36, or over 53%, to close at $6.39 on October 2, 2015, thereby injuring Amicus investors. News of the delay in the FDA approval process comes shortly after the Company completed an offering of securities to the public.

If you purchased Amicus securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151009006002/en/

Contacts:

Glancy Prongay & Murray LLP, Los Angeles
Lesley Portnoy, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com

Source: Glancy Prongay & Murray LLP